The use of medical cannabis as a possible treatment for ASD has caught the attention of researchers worldwide, with Israel leading in global medical cannabis research. The endocannabinoid system of the body is a regulatory feedback system which influences the function of many other systems – neurotransmitters, hormones and more. This means that it tells the body to send more or less of these other chemicals to where they are needed. The endocannabinoid system sends its messages via cannabinoids that are produced’ in house’ (CB1 and CB2) and there are receptors for these cannabinoids on almost all parts of the body. When the endocannabinoid system isn’t working right, the body isn’t getting the information it needs to know how much and where to send various other chemicals and imbalances can then occur.
It has been observed that individuals with ASD may lack certain cannabinoids normally found in the human body (Lower circulating endocannabinoid levels in children with autism spectrum disorder). The theory of treatment with medical cannabis is to give the body the plant-based version of the cannabinoids that are lacking. This will restore balance to the endocannabinoid system and thus to the various systems under its influence. In studies performed in Israel treating children with ASD with medical cannabis, significant improvement was observed in many of the core issues of ASD including speech, social interaction, challenging behaviors and more.
Cannabis is also a strong anti-inflammatory and can have significant immune-modulating effects in the body. See: Healing autism spectrum disorder with cannabinoids: a neuroinflammatory story
At Cell-El Ltd., we are interested in investigating potential improvements in speech, social skills, and other behavioral measures through a range of biomedical interventions, while examining the associated changes in biomarkers. We hope to have the opportunity to analyze biological markers in children with autism spectrum disorder (ASD) before and after various treatments, including medical cannabis. This approach will enable Cell-El to generate objective data and deepen the understanding of the biological changes induced by cannabis in children with ASD. Cell-El strives to develop an objective, biomarker-based test that can serve as a tool for guiding treatment and evaluating its outcomes across a variety of therapeutic interventions.
For more about ASD-cannabis studies from Cell-El study partners see:
- Effects of Medical Cannabis Treatment for Autistic Children on Family Accommodation: An Open-Label Mixed-Methods Study (2025)
- Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems—A Retrospective Feasibility Study (2018)
Additional research studies of interest:
- Effects of Medical Cannabis Treatment for Autistic Children on Anxiety and Restricted and Repetitive Behaviors and Interests: An Open-Label Study (2024)
- Cannabinoid treatment for the symptoms of autism spectrum disorder (2023)
Help Us Help You
Better diagnostics for ASD based on laboratory-measured objective biomarkers can possibly enable researchers and clinicians to provide more precise and personalized treatment. You too can make a difference in the lives of children with ASD and their families by joining the Cell-El study. Cell-El is recruiting mothers and their infants aged 10-18 months who have not been diagnosed with ASD but who have a sibling diagnosed with ASD.
Please contact Leah at [email protected] or fill out the form to find out about eligibility to participate in our diagnostic study and please help spread the word about the Cell-El study. Sharing our study will enable our important biomarker diagnostic tool to be integrated into autism treatment as quickly as possible.
